COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,738 Articles (22,502 medRxiv, 8,236 bioRxiv)

Most recent first Previous |  Page 2841: Articles 28401-28410  | Next

Between-centre differences for COVID-19 ICU mortality from early data in England
Qian, Z., Alaa, A. M., van der Schaar, M., Ercole, A.
10.1101/2020.04.19.20070722 — Posted: 2020-04-27
Quality control of low-frequency variants in SARS-CoV-2 genomes
Rayko, M., Komissarov, A.
10.1101/2020.04.26.062422 — Posted: 2020-04-27 Discussion: Onsite
Specific mutations in SARS-CoV2 RNA dependent RNA polymerase and helicase alter protein structure, dynamics and thus function: Effect on viral RNA replication
Begum, F., MUKHERJEE, D., DAS, S., THAGRIKI, D., TRIPATHI, P. P., BANERJEE, A. K., RAY, U.
10.1101/2020.04.26.063024 — Posted: 2020-04-27
Coronavirus, as a source of pandemic pathogens.
Konishi, T.
10.1101/2020.04.26.063032 — Posted: 2020-04-27
Emergence of multiple variants of SARS-CoV-2 with signature structural changes
Bhowmik, D., Pal, S., Lahiri, A., Talukdar, A., Paul, S.
10.1101/2020.04.26.062471 — Posted: 2020-04-27
Role of 1'-Ribose Cyano Substitution for Remdesivir to Effectively Inhibit both Nucleotide Addition and Proofreading in SARS-CoV-2 Viral RNA Replication
Zhang, L., Zhang, D., Yuan, C., Wang, X., Li, Y., Jia, X., Gao, X., Yen, H.-L., Cheung, P., Huang, X.
10.1101/2020.04.27.063859 — Posted: 2020-04-27 Discussion: Onsite
Disparate temperature-dependent virus - host dynamics for SARS-CoV-2 and SARS-CoV in the human respiratory epithelium
V'kovski, P., Steiner, S., Gultom, M., Kelly, J. N., Russeil, J., Mangeat, B., Cora, E., Pezoldt, J., Holwerda, M., Kratzel, A., Laloli, L., Wider, M., Portmann, J., Thao, T. T. N., Ebert, N., Stalder, H., Hartmann, R., Gardeux, V., Alpern, D., Deplancke, B., Thiel, V., Dijkman, R.
10.1101/2020.04.27.062315 — Posted: 2020-04-27 Discussion: Onsite
Structure of replicating SARS-CoV-2 polymerase
Hillen, H. S., Kokic, G., Farnung, L., Dienemann, C., Tegunov, D., Cramer, P.
10.1101/2020.04.27.063180 — Posted: 2020-04-27
Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.
Pruijssers, A. J., George, A. S., Schäfer, A., Leist, S. R., Gralinski, L. E., Dinnon, K. H., Yount, B. L., Agostini, M. L., Stevens, L. J., Chappell, J. D., Lu, X., Hughes, T. M., Gully, K. L., Martinez, D. R., Brown, A. J., Graham, R. L., Perry, J. K., Du Pont, V., Pitts, J., Ma, B., Babusis, D., Murakami, E., Feng, J. Y., Bilello, J. P., Porter, D. P., Cihlar, T., Baric, R. S., Denison, M. R., Sheahan, T. P.
10.1101/2020.04.27.064279 — Posted: 2020-04-27 Discussion: Onsite
A SARS-CoV-2 vaccine candidate would likely match all currently circulating strains
Dearlove, B. L., Lewitus, E., Bai, H., Li, Y., Reeves, D. B., Joyce, M. G., Scott, P., Amare, M., Vasan, S., Michael, N. L., Modjarrad, K., Rolland, M.
10.1101/2020.04.27.064774 — Posted: 2020-04-27

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).